Mastodon Pallimed

Wednesday, January 14, 2009

WaPo On Death in America

Washington Post recently published a commentary, written by a hospitalist, about the modern American way of dying. Well written, with lots of familiar patient scenarios. It tends towards the philosophical side, and seems to place the burden of the problem on patients, the culture at large, etc., as opposed to our medical system and culture. Of course that's a problem, but I don't think it's one that any clinician is going to fix, and the question for us clinicians is how can we impact this within the medical system (as we are not going to revolutionize our overall society's approach to death and dying)? Anyway - worth a read:

Everyone wants to grow old and die in his or her sleep, but the truth is that most of us will die in pieces. Most will be nibbled to death by piranhas, and the piranhas of senescence are wearing some very dull dentures. It can be a torturously slow process, with an undeniable end, and our instinct shouldn't be to prolong it. If you were to walk by a Tilt-A-Whirl loaded with elderly riders and notice that all of them were dizzy to the point of vomiting, wouldn't your instinct be to turn the ride off? Or at the very least slow it down? Mercy calls for it. This isn't about euthanasia. It's not about spiraling health care costs. It's about the gift of life -- and death. It is about living life and death with dignity, and letting go. In the past, the facade of immortality was claimed by Egyptian kings, egomaniacal monarchs and run-of-the mill psychopaths. But democracy and modern medical advances have made the illusion accessible to everyone. We have to rid ourselves of this distinctly Western notion before our nation's obesity epidemic and the surge of aging baby boomers combine to form a tsunami of infirmity that may well topple our hospital system and wash it out to sea.

At some point in life, the only thing worse than dying is being kept alive.

Thanks to Dr. Fred Holm for alerting me to this.

Wednesday, January 14, 2009 by Drew Rosielle MD ·

Pall-Pourri

Some ramblings on recent papers piling up from JAMA & Journal of Clinical Oncology, following two tenuous threads of 'whopping' and 'modest but measurable.'

JAMA has a brief discussion of allowing terminally ill patients access to experimental drugs (written in the context of the 'Abigail Alliance' ruling see here & multiple posts here). The commentary is not about the Abigail decision(s) per se - about whether patients have the right to obtain experimental drugs - but more a practical discussion of how best to allow patients access - balancing interests, minimizing exploitation, etc.

JAMA also continues its 'perspectives on care at the close of life' series with a review of agitation and delirium at the end of life. Nicely done & good for the teaching file.

Continuing on with JAMA - a randomized trial of deep-brain stimulation vs. best medical therapy for patients with Parkinson's disease has been published. I am in no position to be a good judge of the clinical import of the findings - the major outcome evaluated was time spent in the 'on' state without significant dyskinesias as measured by self-reported patient motor diaries (which seems a somewhat troubling measurement tool particularly given that this was not a blinded study as patients knew whether they had hardware in their brains or not). Patients who received DBS had substantially more 'good motor function' hours a day (4.5 overall) than the best medical therapy patients (which sounds pretty good to me), although at a cost. A whopping 40% had serious adverse events due to the surgery (infections, etc.), and even at 6 months there were some ongoing trade-offs (some increased depression, more falls, mild cognitive decrements) in the DBS patients. I mention the study in large part because interventions like this (up front risky/invasive, costly device therapies/interventions which however may improve either longevity or quality of life in a substantial number of patients - think LVADs) continue to become more common, our patients with highly morbid and/or life-limiting diseases are going to be facing decisions about these interventions more and more (whether to try them, managing complications from them, struggling with considering stopping them), and palliative care folks will be called upon more and more to help patients with those decisions.

JCO recently had a look at the natural history of bisphosphonate associated osteonecrosis of the jaw in multiple myeloma patients. A whopping 26% of patients did not heal over the course of the study (sufficient patients are still enrolled and being followed such that the median follow-up time has not yet been reached: minimum follow-up has been 3.2 years for the cohort).

JCO
also has another study looking at the quality of life impact of prophylactic whole brain radiation for patients with extensive stage small cell lung cancer (yes, at least on a time frame of 3 months, it has a modest but measurable impact on health related quality of life for the worse).

Finally, there's a fascinating randomized (routine-care-controlled) study involving giving advanced lung cancer outpatients a quality of life diary (they were asked to fill out a QOL questionnaire once a week and were encouraged to bring concerns to their providers). They found that those who were given the diary had, yes, modest but measurable decrements in their health related quality of life. The diary, if it did anything, seemed to make the patients feel worse. Most diary patients didn't however share their concerns, questionnaire results, etc. with their providers. It's a fascinating study, and if you believe the results a good warning - giving patients these measurement tools without any system for responding to them, any monitoring or routine evaluation of the patients' questionnaire responses, may actually make them feel worse.

It seems we clinicians are stuck in the unfortunate position of having to ask our patients how they are doing.....

by Drew Rosielle MD ·

Friday, January 9, 2009

Changing treatment preferences in CHF

Journal of the American College of Cardiology has a paper looking at changing treatment preferences for survival after a hospitalization for heart failure. The data come from a prospective trial of hospitalized heart failure patients (N=404, mean age in upper 50s) in which treatment preferences for quality (actually health status) vs. quantity of life were measured using 'time-trade off' methods. Their description of TTO is below - basically ranged from scores from 0 (completely values quality of quantity) to 1 (quantity over quality):

The TTO instrument was administered verbally by the study nurse at 1, 2, 3, and 6 months. Whenever possible, this instrument and written questions were administered in the absence of family. After a scripted introduction, the initial question was “Would you prefer living 2 years in your current state of health or living 1 day in excellent health?” An answer of 1 day, equated to a utility of 1/730 (not, vert, similar0), would end the script. An answer of 2 years would be followed by the next choice, between living “2 years in your current state of health or living 1 year 11 months in excellent health.” After sequential choices, the number of months (up to 24 months) in excellent health that the respondent considered to be equivalent in value to 24 months of survival in current health was recorded, and this ratio was the utility (between 0 and 1). The number of months at the indifference point subtracted from 24 yielded the number of months of survival time that the patient would be willing to trade.
Complex, yes I know, and there's a good (and historically minded) discussion of this method given in an excellent accompanying editorial.

They found a distinct bi-modal distribution of answers: 40% of patients more or less said they'd trade no time, 28% said they'd trade nearly 2 years of time to be in excellent health, with a smattering of the rest in between. Demographics including age and ethnicity didn't predict which group patients belonged to, although functional status did (with those willing to trade 2 years having the worst 6 minute walk test results - 60 meters [which is terrible]). Other interesting findings:
  1. Preferences didn't change much over time (on average just by 4% using the TTO 'scale). However those that did change substantially (a minority of patients had relatively large changes), most of those changed with preferences for increased survival time.
  2. Changing preferences for increased survival time were associated with improved functional status/decreasing symptoms. (Most patients had improved functional status and decreasing symptoms anyway - as one would expect given that at baseline these patients were hospitalized with heart failure - however those whose preferences changed the most had a more pronounced improvement in symptoms than the others).
  3. Preferring quality over time was associated with earlier death: 30% of the patients who died by 180 days preferred quality over time, compared to only 6% of those who survived 180 days. Given that these patients were sicker (as mentioned by functional status) at baseline and that this data come from a trial of using pulmonary artery catheters in CHF management (ie these were patients willing to receive PA catheters and so were likely also receiving/willing to receive 'aggressive' care) these preferences were likely markers of poor prognosis, as opposed to causes of it.
I find papers like this interesting academically, although how they inform practice is less clear given that I assume ideal practice involves frequently re-clarifying patient goals for all patients with severe chronic and/or life-limiting diseases. Nevertheless it's always interesting to see how preferences do change, and it's important for us in palliative care to be aware that how a patient feels when s/he is quite ill/symptomatic may change if they feel better. Obviously a substantial minority of hospice patients (particularly non-cancer ones) either 'graduate' or sign-off of hospice care after a time, and one reason for this may very well be the phenomenon measured in this study: goals of care are set/decisions are made often in acute settings (e.g. during an acute illness in a hospitalization) - in those patients who recover, improve a little, their treatment preferences may change as well.

ResearchBlogging.orgL STEVENSON, A HELLKAMP, C LEIER, G SOPKO, T KOELLING, J WARNICA, W ABRAHAM, E KASPER, J ROGERS, R CALIFF (2008). Changing Preferences for Survival After Hospitalization With Advanced Heart Failure Journal of the American College of Cardiology, 52 (21), 1702-1708 DOI: 10.1016/j.jacc.2008.08.028


Thanks to Dr. Bob Arnold for this.

Friday, January 9, 2009 by Drew Rosielle MD ·

Aging & Cancer

Cancer recently devoted an entire supplemental issue to cancer & aging. I'll briefly note a few of the papers.

This paper is a good general review of the clinical & research issues in 'geriatric oncology' - clearly the major perspective here is that chronological age is less important than co-morbidities/functional age, etc.

There is a review of end-of-life care planning and its effects on EOL care/decision-making. It talks about advance directives and their well-described limits, as well as offers a chatty, case-based discussion of what actually constitutes EOL planning/discussion. It has a distinctly psychological focus, and says this towards the end about what's needed in the future:

Policies also must require changes in practitioner performance; it is insufficient to frame policies solely for patients and families. These policies will include changes in medical education and updating how practitioners frame their exchanges with patients. Although being nice, respectful, and a good listener are essential, more is required. Practitioners need a framework that allows them to communicate effectively and to explore how the perceptions and beliefs of a patient and their family about disease and treatment affect how they process the information they receive from oncologists and how they interpret and assign meaning to their ongoing experience with disease and treatment. The understanding emerging from these processes affects patients' treatment preferences and decisions. Patients can frame these gains and losses either abstractly, as days and weeks alive, or concretely, in a realistic view of functioning and surviving to experience significant, vivid, worthwhile life events. Policy must call for and implement educational experiences to achieve this goal.
I agree with this, of course, but also note that that's a really tough thing to teach people - some clinicians sort of 'get it' anyway - but those that don't, being taught how to figure out what a patient's understanding is, how they make decisions, their 'narrative' so to speak - that's not a task that can be packaged into a review article or lecture and requires a lot of ongoing time, support, reflection, and mentoring. What I'm saying is that I'd like to know what exact 'policies' the authors have in mind....

The other article is about 'dual process theories' and decision making. It is an incredibly wonkish (written by all PhDs) paper describing psychological research regarding affective (emotional, experiential) decision making and deliberative (cognitive, intellectual) decision making; how age may affect this; and speculating on how this may all affect cancer decision making. If you're interested in this sort of stuff it's a window into the psychological-research world regarding decision making but I can't say it has any easily applicable clinical relevance.

by Drew Rosielle MD ·

Wednesday, January 7, 2009

More Good Blogs to Follow

I have been following Jessica Knapp's blog The Good Death since she came to my attention in some Google Alerts during the run up to the voting on the Washington State I-1000 Medically Assisted Death Initiative. From her About Me Section:
I have always been interested in the way people communicate. In 2004, I earned my MA in communications from Fordham University. Before that, I worked for two years as a research assistant in bioethics, and during that time, I found myself particularly interested in the issues surrounding the way we talk about death and dying. Over the past year, I had a health scare myself, and closely following that, my grandfather died in about the worst possible way you can—in the hospital, hooked up to tubes, with family not completely sure whether they were doing the right thing by letting him go. All of these factors have led me to decide to pursue my PhD in communications with the goal of improving the way we communicate about death. It is something everyone will face, and in America, most of us are afraid to talk about. We need to get better at talking about it so that we can have better deaths. Also, because death can be such a dark and trying subject to deal with, and because I am also a student of media studies, you will see some pop-culture references to death on this site.
Here is a sampling of her posts:

Cybertime - Describing her mother opening an unused email account that her deceased husband had been sending emails to before he died.

Televised Assisted Suicide - About Kevorkian and the recent televising of the act in Britain.

Fantastic Death - An excerpt from a recent book she read.

Another blog I only discovered last week is the only blog I know written by a hospice chaplain. We practically have a hospice team of blogs now! The blog Rainy Nights is written by Ken Bradstock (D. Min.) and combines some personal reflections, some patient stories (names and details changed for HIPPA), and the occasional poem.

Here are some examples of his posts:

How Nice - a poem about the difference between clinical staff and adminsitration.

Book of James
- How do you minister a minister?

And lastly, Confessions of a Young Looking Social Worker should hopefully intrigue you enough to check the blog out. (Yes! Now we have a core hospice/palliative care team) The blog is a mix of personal reflections (i.e. the White Sox) and the occasional fictionalized/altered accounts of interactions with staff and patients. There have not been a lot of hospice related posts lately, but here are a few choice ones:

Cross It Off The List - Taking a patient skydiving? Call your hospice social worker!

Ruth
- "My favorite patient is dying..."

If you know of any other good hospice & palliative medicine oriented blogs feel free to post them in the comments or email me at ctsinclair - a - t - gmail d0t com.

Hospice & Palliative Medicine Blogs
(in order of age of blog)
**just added**

Reblog this post [with Zemanta]

Wednesday, January 7, 2009 by Christian Sinclair ·

New Options to Share Pallimed with Others

The posts on the website have a new look on the footer this new year. The multiple buttons to share a post you find interesting on Pallimed have been consolidated into a Share This button. It looks something like this:When you click on it a small window opens to give you the option to bookmark it to several social networking sites (Facebook, Del.ico.us, Google Bookmarks, Technorati, etc.), email to a friend, or post on your own blog (similar to the reblog feature). If there are ones you prefer, but do not see them, let me know, and I will add them.

If you use any of the web tools or social networks, we encourage you to tag any Pallimed post you like. By doing so it raises the awareness of palliative medicine issues to the web in general since others may stumble upon the post at the aggregations sites. If you don't use any of them, might I encourage you to consider the following:

RSS reader: Google Reader
Social Bookmarking: del.ico.us
Social Networking: Facebook (has a Pallimed readers group, palliative medicine fellows group and AAHPM group) or LinkedIn (has a AAHPM group)

Here are some quick videos to teach you what they are if you are not familiar with them (email subscribers click the title of the post to view):

RSS Reader


Social Bookmarking


Social Networking

Reblog this post [with Zemanta]

by Christian Sinclair ·

2008 Medgadget Medical Blog Awards Final Nominations

The final nominees for various categories of best medical blogs have been announced on Medgadget, and alas Pallimed did not get into the finalists for Best Clinical Sciences Blog. Many thanks again to Paul Levy of Running a Hospital for nominating us.

The nominees in this and the other categories are very good blogs and I am particularly happy to see Medical Futility nominated as one of the Best Health Policy/Ethics Blogs. If you are a fan of his blog feel free to head on over to vote for him and peruse the other nominees. (Here you can find the longer list of all blogs intially nominated.)

Good luck to all the nominees! Voting ends January 18th.

by Christian Sinclair ·

Monday, January 5, 2009

Depression in Parkinson's

Neurology has published a randomized controlled comparison of nortriptyline with paroxetine for depression in patients with Parkinson's disease. It's a rare treat to see a decently designed, controlled trial of depression treatment in a palliative-care-relevant population (when was the last time we've seen a controlled drug trial of depression therapy in advanced cancer patients?).

This was an 8 week, NIH-funded, randomized comparison of nortiptyline (starting dose 25 mg), paroxetine CR (starting dose 12.5 mg), and placebo in 52 patients (median age ~63 years) with Parkinson's disease. Patients were seen at 2, 4, and 8 weeks and doses were titrated per the treating physician's discretion (mean doses at the end of the study were ~50 mg of nortriptyline and 30 mg of paroxetine). They used changes in depression symptoms measured by the Hamilton Depression Rating Scale for their primary outcome. No power analysis was done.

Overall, nortriptyline looked better than paroxetine. At 2 and 4 weeks nortriptyline patients had significantly greater decreases in depression symptoms compared to paroxetine; by 8 weeks this was a non-significant trend. Nortriptyline was superior to placebo at all points; paroxetine was not (trended better; not statistically significant). Again - no power analysis was done and so there's a good risk of 'type II' error here in concluding paroxetine is genuinely 'no better' than placebo. In looking at the percent of patients who had a 50% reduction in their HDRS score, nortriptyline again looked much better than paroxetine (~50% of patients vs. 11% with paroxetine being no better than placebo for this outcome). Symptoms/side effects/drop-outs were similar across all groups, including orthostatic hypotension, although the study was certainly not powered to detect any differences.

The authors note in their discussion that the other controlled trials of SSRIs in Parkinson's disease patients did not support their efficacy either. Despite the small size of the study nortriptyline seemed to be consistently, and by different analyses, better than paroxetine, without any obvious differences in side effects, although one wonders if those would have emerged in a larger trial. The authors speculate that norepinephrine (and not serotonin) may have a particular role in the pathophysiology of depression in Parkinson's disease which is why nortriptyline was more effective. Given that, a trial of norepinephrinergic antidepressants (duloxetine, venlafaxine) seems to be in order. Overall I think the findings are pretty compelling.

ResearchBlogging.orgM. Menza, R. DeFronzo Dobkin, H. Marin, M. H. Mark, M. Gara, S. Buyske, K. Bienfait, A. Dicke (2008). A controlled trial of antidepressants in patients with Parkinson disease and depression Neurology DOI: 10.1212/01.wnl.0000336340.89821.b3

Reblog this post [with Zemanta]

Monday, January 5, 2009 by Drew Rosielle MD ·

'2nd generation' antidepressants in Annals

And more on depression....

Annals of Internal Medicine recently had a couple articles on '2nd generation' antidepressants. (2nd generation here means SSRIs and other/newer antidepressants that have emerged in the last couple decades.) The first is a clinical practice guideline on 2nd generation ADs, and the second is the metaanalysis looking at the comparative efficacy of 2nd gen ADs which is the basis of the practice guideline. These are good ones for the teaching file - compiles a large amount of the comparative research on newer ADs.

The overall finding is that the vast majority of the research data support the idea that all of these agents are similarly effective for treating depression (where they have been compared, they have nearly uniformly shown to have comparable efficacy). What I found most interesting was the comparison of other outcomes, some of which are of particular importance in our patient population: 1) apparently there have been several studies showing that mirtazapine has a faster onset of action (symptom alleviation) than SSRIs, although by 4 weeks this effect is no longer apparent, 2) there is no clear evidence that any newer AD is better/worse than any others regarding alleviating anxiety symptoms associated with depression (with the exception of venlafaxine likely being better than fluoxetine), 3) nausea and vomiting are the most common reason for discontinuation of ADs (in the trials) with venlafaxine probably having more N/V than other ADs, and 4) duloxetine appears to be no better than SSRIs (at least paroxetine) in the treatment of pain associated with major depressive disorder (which is not to say that it's no better for other types of pain).

by Drew Rosielle MD ·

'Between utter despair and essential hope'

Journal of Clinical Oncology has an 'Art of Oncology' piece about denial and hope. It starts as a discussion of 'denial' (framing it as a normal coping mechanism in the initial aftermath of hearing life-altering news):

Patients tend to perceive a diagnosis of cancer as if they were in a movie. Professional experience educates: it is most often of no use to try to drag patients, or their family members, out of this movie. Psychologists and doctors conscientiously have to know that, although the diagnosis and facts may be explained more than once, even then patients often do not accept the facts. Patients with a cognitive escape-avoidance coping were reported to have a longer survival than other patients with localized melanoma. At some time, the patient will get over this state of shock. The time for a first psychic consolidation of reality awareness will come.
It then goes on to discuss patients moving from denial to other stages - using the 'Renz model of maturation' - and describes in somewhat spiritual terms this process:
The third stage consists of nothing less than transformation. What happens is more than just being able to accept. It is a gift of grace beyond human endeavor and power. It is here where the spiritual dimension comes in, so that patients momentarily, or for a while, feel different. There is happiness and well-being in the midst of illness. In the course of the dying process, spiritual experiences of such intensity often happen more than just once. After a shorter or longer struggle, patients reach a new mental state, just as a gift of grace.
Ok, well, not somewhat spiritual terms but explicitly spiritual terms. What struck me about this was not that I don't know what the authors are talking about. We all see amazing things every day in this line of work - life-transformations, patients in unbelievably horrible circumstances coping with truly humbling serenity and generativity, etc. - and I'll be the first to admit that I find this a 'mysterious' process. Why it happens with some patients/families and not others? If clinicians actually have some power over it (to foster it, to help cause these 'positive' transformations, etc.)?

That said, and with all acknowlegments to the critical importance of faith, religion, and/or spirituality in our patients' lives, I still am hesitant for us as a community to use spiritual language to describe such events. "It is a gift of grace beyond human endeavor and power" strikes me as an incredibly therapeutic nihilistic statement: both our patients and us as clinicians are passive witnesses to this, as how could we have an impact on something beyond our power? The fact that the process appears mysterious does not mean it is describable/understandable in spiritual terms alone, and doing so takes it out of the realm of inquiry, understanding, and intervention. I am probably over-reacting, but language is important....

by Drew Rosielle MD ·

Pallimed | Blogger Template adapted from Mash2 by Bloggermint